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The objective of this study is to assess the response of telemetered common marmosets to 
multiple cardiac ion channel inhibitors and to clarify the usefulness of this animal model in 
evaluating the effects of drug candidates on electrocardiogram (ECG). Six multiple cardiac ion 
channel inhibitors (sotalol, astemizole, flecainide, quinidine, verapamil and terfenadine) were 
orally administered to telemetered common marmosets and changes in QTc, PR interval and 
QRS duration were evaluated. Drugs plasma levels were determined to compare the sensitivity 
in common marmosets to that in human. QTc prolongation was observed in the marmosets 
dosed with sotalol, astemizole, flecainide, quinidine, verapamil and terfenadine. PR 
prolongation was noted after flecainide and verapamil administration, and QRS widening 
occurred following treatment with flecainide and quinidine. Drugs plasma levels associated with 
ECG changes in marmosets were similar to those in human, except for astemizole- and 
verapamil-induced QTc prolongation. Verapamil-induced change is suggested due to body 
temperature decrease, and sensitivity to astemizole-induced change in marmosets is considered 
similar with that in dogs and monkeys. These results indicate that telemetered common 
marmoset is a useful animal model for evaluation of the ECG effects of drug candidates 




り、これまで様々な非臨床催不整脈性評価系が開発されてきた。In vitroおよび ex vivo評価系は、
より少量の被験物質でリスク評価可能な点で優れており、現在、それらの評価結果からヒト心電図


























Table 1 Variations in PR interval, QRS duration and QTc in measured absolute value (A) and 
























All the vehicle control data (from 18 common marmosets) were aggregated at each time point. 
 
(A) Absolute value  (B) Change from pre-value ( value) 
PR(msec)           PR(msec)          
  Time after dosing (hr)      Time after dosing (hr)   
Time Pre 1 2 4 6 8 24  Total  Time Pre 1 2 4 6 8 24  Total 
N 18 18 18 18 15 3 18  108  N 0 18 18 18 15 3 18  90 
Mean 50 50 50 50 51 52 51  50  Mean - 0 0 0 1 1 0  0 
S.D. 4 4 5 5 5 7 5  5  S.D. - 2 2 2 2 1 2  2 
Max 56 56 57 57 55 58 56  58  Max - 5 3 3 6 2 6  6 
Min 42 43 41 40 40 45 41  40  Min - -3 -3 -3 -3 0 -4  -4 
                     
QRS(msec)           QRS(msec)          
  Time after dosing (hr)      Time after dosing (hr)   
Time Pre 1 2 4 6 8 24  Total  Time Pre 1 2 4 6 8 24  Total 
N 18 18 18 18 15 3 18  108  N 0 18 18 18 15 3 18  90 
Mean 27 26 27 26 27 24 27  27  Mean - 0 0 0 0 0 0  0 
S.D. 2 2 2 2 2 3 3  2  S.D. - 1 1 1 1 1 1  1 
Max 29 29 29 29 30 27 29  30  Max - 2 2 1 1 1 2  2 
Min 22 22 21 22 21 21 20  20  Min - -1 -1 -1 -1 -1 -2  -2 
                     
QTc(msec) 
       
 
 
 QTc(msec)          
  Time after dosing (hr)      Time after dosing (hr)   
Time Pre 1 2 4 6 8 24  Total  Time Pre 1 2 4 6 8 24  Total 
N 18 18 18 18 15 3 18  108  N - 18 18 18 15 3 18  90 
Mean 146 144 145 143 148 143 148  145  Mean - -2 -1 -3 1 0 2  -1 
S.D. 11 11 13 12 13 10 14  12  S.D. - 4 5 4 5 7 6  5 
Max 172 163 171 165 180 150 188  188  Max - 4 5 4 9 8 16  16 





チ心筋イオンチャネル阻害剤とその心筋イオンチャネル阻害能および評価時点を示す (Table 2）。 
 
Table 2 Molecular weight, cardiac ion channel inhibitory potential and time points for ECG 








いずれの化合物もコモンマーモセットにおいて心電図異常を生じた。Sotalol は QTc 延長を、
astemizoleは QTc延長を、flecainideは PR延長、QRS延長および QTc延長を、quinidineは QRS
延長および QTc延長を、verapamilは PR延長および QTc延長を、terfenadineは QTc延長を引き
起こした (Figure 1）。いずれの変化も絶対値を用いた評価より Δ値を用いた評価の方がより低濃度、
あるいはより多くの評価時点で検出された (Table 3）。Verapamil の QTc 延長以外の変化は臨床に
おいても報告されており、また、コモンマーモセットにおいて変化が認められなかった心電図パラ
メータは臨床においても報告がない。Verapamil投与後の QTc延長は体温低下と良く相関していた







Test article Molecular weight 
IC50 ( μM) Time points (hr post-dose) 





Sotalol 272.4 111.4 193.3 7013.9 1, 2, 4, 8, 24 1, 2, 4, 8 
Astemizole 458.6 0.0009 1.1 3.0 
1, 2, 4, 6, 24 1, 2, 4, 6 
Desmethylastemizole 444.5 0.001 N.D. N.D. 
Flecainide 414.3 1.5 27.1 6.2 1, 2, 4, 6, 24 1, 2, 4 
Quinidine 324.4 0.72 6.4 14.6 1, 2, 4, 6, 24 1, 2, 4, 6 
Verapamil 454.6 0.25 0.20 32.5 1, 2, 4, 6, 24 1, 2, 4, 6 
Terfenadine 471.7 0.0191 0.93 2.0 1, 2, 4, 6, 24 1, 2, 4, 6 
 
Figure 1 Effects of sotalol (A), astemizole (B), flecainide (C), quinidine (D), verapamil (E) and 
terfenadine (F) on ECG parameters in conscious common marmoset. 
Time course of ECG parameters after oral administration of sotalol, astemizole, flecainide, quinidine, verapamil 
and terfenadine are shown in change from pre-value. The closed symbols represent statistically significant 
changes from the corresponding vehicle control value (p<0.05, compared with the vehicle-treated data). #: 
Judged to be significant and the symbols were filled since the changes noted in 2 common marmosets 
exceeded the range of any vehicle control data, although the statistical analysis was not conducted. Data are 
presented as mean. 
Table 3 Summary of the change in ECG parameters induced by multiple cardiac channel inhibitors 





Number of time points at which 
ECG change was noted 
A Δ A Δ 
Sotalol QTc - 15 0 5 
Astemizole QTc 30 30 3 4 
Flecainide 
QTc 45 15 3 4 
PR 45 45 2 3 
QRS 45 45 3 3 
Quinidine 
QTc 50 10 4 5 
QRS 50 50 2 1 
Verapamil 
QTc 150 150 2 2 
PR - 150 0 3 
Terfenadine QTc 100 30 5 6 
The lowest observed effect level for ECG parameter change by each test article and the number of time points 
at which change in ECG parameter was noted are summarized. LOEL: the lowest observed effect level. A: 
Absolute value. Δ: Change from pre-value. 
 
 
Figure 2 Relationship between changes in body temperature and QTc after oral administration of 
verapamil. 
The relationship between QTc and body temperature after oral administration of verapamil is shown. Individual 







その結果を Table 4 に示す。心電図異常発現時の非結合型血中濃度は、コモンマーモセットとヒト
において、astemizole による QTc 延長および verapamil による QTc 延長を除く全ての心電図変化
が同等の血中曝露下 (4倍以内の乖離)で認められていることが確認された。Astemizoleの QTc延長
はヒトよりコモンマーモセットの方が高曝露下でないと検出されていなかった (14.5倍以上の乖離)。
Astemizole 投与後の QTc 延長には、同等の hERG 阻害活性を持つ代謝物 desmethylastemizole の
関与が示唆されており、Table 5に示す通り、コモンマーモセット、ヒト、ビーグルイヌ、カニクイ






Table 4 Plasma unbound levels of sotalol, astemizole, flecainide, quinidine, verapamil and 
terfenadine, at which ECG parameter changes were noted or reported in common marmoset, 









CM  H  D & M  CM / H 
CM / 







 (D) 3073  1.3 - 3.8 1.3 
H: Redfern, et al., 2003 
H: Gotta, et al., 2016  




0.247  <0.0165  N.A.  >14.5 N.C. 
H: Redfern, et al., 2003 
H: Vorperian, et al., 1996 
D: Toyoshima, et al., 2005 




625  660  N.D.  1 N.C. 
H: Salerno, et al., 1986 H: 
Bergenholm, et al., 2017 
D: Herbert, et al., 2011 
PR 
prolongation 
1838  669  (D) 996  2.7 1.8 
QRS 
widening 




163  97-224  
(D) 395 
(M) 166 
 0.7 - 1.7 0.4 - 1.0 
H: Redfern, et al., 2003 
H: Bergenholm, et al., 2017 
D: Toyoshima, et al., 2005 
D: Cros, et al., 2012  
M: Ando, et al., 2005a 
M: Akabane, et al., 2010 
QRS 
widening 
240  599  
(D) 908 
(M) N.D. 




45  N.A.  N.D.  N.C. N.C. H: Bergenholm, et al., 2017 
D: Herbert, et al., 2011 
M: Ando, et al., 2005 
PR 
prolongation 
45  94  
(D) 17.6 
(M) N.D. 




0.05  0.09  
(D) 6.52 
(M) N.A. 
 0.6 0.008 
H: Redfern, et al., 2003 
D: Van Deuren, et al., 2009 
D: Webster, et al., 2001 
M: Ando, et al., 2005 
Data for common marmosets are based on the results of this study. Data for beagle dog, cynomolgus monkeys 
and human are reported in the literature. N.A.: Not available due to a lack of protein binding ratio data. N.D.: 
Not detected even at the highest dose. N.C.: Not calculated. CM: Common marmoset, H: Human, D: Dog, M: 
Monkey. 
 
Table 5 Plasma concentration of astemizole and desmethylastemizole at QTc prolonged dose 
in human, common marmoset, monkey and dog. 
Species 
Unbound plasma concentration 
(ng/mL) 
Total plasma concentration 
(ng/mL) 
Reference 
A D A D A + D  
Human <0.0165 N.A. <0.5 7.7 <8.2 
Redfern, et al., 2003 
Vorperian, et al., 1996 
Common 
marmoset 
0.247 1.15 31 61 92 - 
Cynomolgus 
monkey 
N.A. N.A. 10 230 240 Ando, et al., 2005 
Beagle dog N.A. N.A. 13 15 28 Toyoshima, et al., 2005 
A: astemizole, D: desmethylastemizole, N.A.: Not available due to a lack of protein binding ratio data 
4. 心電図パラメータ変化の各種心筋イオンチャネル阻害との相関 
血漿中濃度を測定した時点について、各心電図パラメータ変化と、血漿中非タンパク結合型被験物
質濃度と各心筋イオンチャネルに対する IC50 との比の相関を示す  (Figure 3）。
Desmethylastemizole は astemizole と同等の強い hERG 阻害活性を示すため、血漿中非結合型被
験物質濃度として両化合物の合計値を用いた。結果、ヒトやその他の動物種での報告と同様に、QTc
延長、PR 延長および QRS 延長はそれぞれ hERG 阻害、Cav1.2 阻害および Nav1.5 阻害との強い
相関が認められた。 
 
Figure 3 Relationship between ion channel inhibition and change in ECG parameters (QTc (A), 
PR (B), QRS (C)) in common marmoset. 
X axis shows a ratio of unbound plasma concentration / IC50 for each cardiac ion channel and Y axis 
shows change from pre-value in QTc, PR interval and QRS duration. 
Astemizole+desmethylastemizole is not included for the relationship analysis with Cav1.2 and 
Nav1.5 because IC50 for Cav1.2 and Nav1.5 of desmethylastemizole have not been reported. The 
closed symbols represent significant changes from the corresponding vehicle control value. #: 
Judged as significant since the changes noted in 2 common marmosets exceeded the range of any 































から、臨床報告と同様、QTc延長、PR 延長および QRS 延長はそれぞれ hERG 阻害、Cav1.2
阻害および Nav1.5 阻害と良く相関することが判明した。 
 以上の研究成績は、コモンマーモセットを用いた心電図評価が医薬品候補化合物のヒト心
電図への作用の予測に有用であり、より効果的な創薬研究に貢献する可能性が示された点で
評価されるため、審査委員会は本論文が博士（創薬科学）に値すると判断した。 
 
 
